H.C. Wainwright raised the firm’s price target on Precigen (PGEN) to $9 from $8.50 and keeps a Buy rating on the shares post the Q3 report. The firm says the Papzimeos launch is generating a “robust” pipeline of patients.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
- Precigen Reports Q3 2025 Results and PAPZIMEOS Launch
- Precigen reports Q3 EPS ($1.06) vs. (9c) last year
- PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Precigen’s Promising Phase 2 Study: PRGN-2009 and Pembrolizumab for Cervical Cancer
- Precigen presents long-term data demonstrating durable responses to PAPZIMEOS